User profiles for Kevin Koch
 | Kevin KochMedical College of Wisconsin Verified email at mcw.edu Cited by 4206 |
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in …
…, SF Jones, JL Harris, DA Smith, KM Koch… - Journal of clinical …, 2005 - ascopubs.org
Purpose This study ( EGF10004 ) assessed the safety/tolerability, pharmacokinetics, and
clinical activity of daily oral dosing with lapatinib ( GW572016 ) in patients with ErbB1-…
clinical activity of daily oral dosing with lapatinib ( GW572016 ) in patients with ErbB1-…
Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor
…, B Hurley, J Lyssikatos, PA Lee, JD Winkler, K Koch… - Clinical cancer …, 2007 - AACR
Purpose: The Ras-Raf-mitogen-activated protein kinase kinase (MEK) pathway is overactive
in many human cancers and is thus a target for novel therapeutics. We have developed a …
in many human cancers and is thus a target for novel therapeutics. We have developed a …
Metal-induced artifacts in MRI
OBJECTIVE. The purpose of this article is to review some of the basic principles of imaging
and how metal-induced susceptibility artifacts originate in MR images. We will describe …
and how metal-induced susceptibility artifacts originate in MR images. We will describe …
[PDF][PDF] Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with …
…, KL Blackwell, DA Smith, KM Koch… - Journal of clinical …, 2005 - academia.edu
… Smith, GlaxoSmithKline; Kevin M. Koch, GlaxoSmithKline; Andrew Stead,
GlaxoSmithKline; Steven Mangum, GlaxoSmithKline; Jennifer Harris, GlaxoSmithKline; Neil …
GlaxoSmithKline; Steven Mangum, GlaxoSmithKline; Jennifer Harris, GlaxoSmithKline; Neil …
Related searches
A multispectral three‐dimensional acquisition technique for imaging near metal implants
Metallic implants used in bone and joint arthroplasty induce severe spatial perturbations to
the B 0 magnetic field used for high‐field clinical magnetic resonance. These perturbations …
the B 0 magnetic field used for high‐field clinical magnetic resonance. These perturbations …
Cerebral blood flow alterations in acute sport-related concussion
Sport-related concussion (SRC) is a major health problem, affecting millions of athletes each
year. While the clinical effects of SRC (eg, symptoms and functional impairments) typically …
year. While the clinical effects of SRC (eg, symptoms and functional impairments) typically …
The role of efflux and uptake transporters in N-{3-chloro-4-[(3-fluorobenzyl) oxy] phenyl}-6-[5-({[2-(methylsulfonyl) ethyl] amino} methyl)-2-furyl]-4-quinazolinamine …
…, KL Olson, LS John-Williams, KM Koch… - Drug metabolism and …, 2008 - ASPET
Lapatinib [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine,
GW572016, Tykerb] is a tyrosine kinase inhibitor …
GW572016, Tykerb] is a tyrosine kinase inhibitor …
MRI after arthroplasty: comparison of MAVRIC and conventional fast spin-echo techniques
OBJECTIVE. The goal of this study was to evaluate the quality of images obtained with a
prototype imaging technique, multiacquisition variable-resonance image combination (MAVRIC)…
prototype imaging technique, multiacquisition variable-resonance image combination (MAVRIC)…
Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas
…, T Hochman, JD Goldberg, KM Koch… - Neuro …, 2012 - academic.oup.com
This single-institution phase II study was performed to estimate the response rate to lapatinib
in neurofibromatosis type 2 (NF2) patients with progressive vestibular schwannoma (VS). …
in neurofibromatosis type 2 (NF2) patients with progressive vestibular schwannoma (VS). …
Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer
…, JW Mier, T Logan, M Atkins, H Koon, KM Koch… - Clinical Cancer …, 2006 - AACR
Purpose: Interleukin-18 (IL-18) is an immunostimulatory cytokine with antitumor activity in
preclinical animal models. A phase I study of recombinant human IL-18 (rhIL-18) was done to …
preclinical animal models. A phase I study of recombinant human IL-18 (rhIL-18) was done to …